{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:32:14Z","timestamp":1794472334229,"version":"4.9.1"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:00:00Z","timestamp":1505865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Following rabies virus (RABV) exposure, a combination of thorough wound washing, multiple-dose vaccine administration and the local infiltration of rabies immune globulin (RIG) are essential components of modern post-exposure prophylaxis (PEP). Although modern cell-culture-based rabies vaccines are increasingly used in many countries, RIG is much less available. The prohibitive cost of polyclonal serum RIG products has prompted a search for alternatives and design of anti-RABV monoclonal antibodies (MAbs) that can be manufactured on a large scale with a consistent potency and lower production costs. Robust in vitro neutralization activity has been demonstrated for the CL184 MAb cocktail, a 1:1 protein mixture of two human anti-RABV MAbs (CR57\/CR4098), against a large panel of RABV isolates. In this study, we used a hamster model to evaluate the efficacy of experimental PEP against a lethal challenge. Various doses of CL184 and commercial rabies vaccine were assessed for the ability to protect against lethal infection with representatives of four distinct bat RABV lineages of public health relevance: silver-haired bat (Ln RABV); western canyon bat (Ph RABV); big brown bat (Ef-w1 RABV) and Mexican free-tailed bat RABV (Tb RABV). 42\u2013100% of animals survived bat RABV infection when CL184 (in combination with the vaccine) was administered. A dose-response relationship was observed with decreasing doses of CL184 resulting in increasing mortality. Importantly, CL184 was highly effective in neutralizing and clearing Ph RABV in vivo, even though CR4098 does not neutralize this virus in vitro. By comparison, 19\u201395% survivorship was observed if human RIG (20 IU\/kg) and vaccine were used following challenge with different bat viruses. Based on our results, CL184 represents an efficacious alternative for RIG. Both large-scale and lower cost production could ensure better availability and affordability of this critical life-saving biologic in rabies enzootic countries and as such, significantly contribute to the reduction of human rabies deaths globally.<\/jats:p>","DOI":"10.3390\/tropicalmed2030048","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T10:57:41Z","timestamp":1505905061000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants"],"prefix":"10.3390","volume":"2","author":[{"given":"Richard","family":"Franka","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carson","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ellison","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Taylor","sequence":"additional","affiliation":[{"name":"East Tennessee State University, James H. Quillen College of Medicine, Johnson City, TN 37614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Smith","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kuzmina","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch, 301 University Blvd, Galveston, TX 50555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Kuzmin","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch, 301 University Blvd, Galveston, TX 50555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Marissen","sequence":"additional","affiliation":[{"name":"Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Rupprecht","sequence":"additional","affiliation":[{"name":"LYSSA LLC, Cummings, GA 30040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., and Cleaveland, S. (2015). Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0003786"},{"key":"ref_3","unstructured":"World Health Organization (2016, August 29). WHO Expert Consultation on Rabies, Second Report. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/85346\/1\/9789240690943_eng.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1016\/j.vaccine.2009.09.034","article-title":"Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines","volume":"27","author":"Franka","year":"2009","journal-title":"Vaccine"},{"key":"ref_5","first-page":"773","article-title":"Laboratory data supporting the clinical trial of antirabies serum in persons bitten by a rabid wolf","volume":"13","author":"Habel","year":"1955","journal-title":"Bull. World Health Organ."},{"key":"ref_6","first-page":"1","article-title":"Monoclonal antibodies for the prevention of rabies: Theory and clinical practice","volume":"4","author":"Nagarajan","year":"2014","journal-title":"Antib. Technol. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/375247","article-title":"Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies","volume":"188","author":"Prosniak","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.med.58.061705.145053","article-title":"A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis","volume":"58","author":"Bakker","year":"2007","journal-title":"Annu. Rev. Med."},{"key":"ref_10","unstructured":"World Health Organization (2017, August 15). WHO Consultation on a Monoclonal Antibody Cocktail for Rabies Post-Exposure Treatment. Available online: http:\/\/www.who.int\/rabies\/resources\/WHO_consultation_on_RMAC_for_rabies_PEP\/en\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: Fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4172\/jaa.1000061","article-title":"Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein","volume":"5","author":"Kuzmina","year":"2013","journal-title":"J. Antivir. Antiretrovir."},{"key":"ref_14","unstructured":"Meslin, F.X., Kaplan, M.M., and Koprowski, H. (1996). The fluorescent antibody test. Laboratory Techniques in Rabies, World Health Organization. [4th ed.]."},{"key":"ref_15","unstructured":"Meslin, F.X., Kaplan, M.M., and Koprowski, H. (1996). A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. Laboratory Techniques in Rabies, World Health Organization. [4th ed.]."},{"key":"ref_16","unstructured":"Jackson, A.C., and Wunner, W.H. (2002). Diagnostic evaluation. Rabies, Academic Press. [1st ed.]."},{"key":"ref_17","first-page":"95","article-title":"BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucleic Acids Symp. Ser."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"M\u00fcller, T., Dietzschold, B., Ertl, H., Fooks, A.R., Freuling, C., Fehlner-Gardiner, C., Kliemt, J., Meslin, F.X., Franka, R., and Rupprecht, C.E. (2009). Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"Minola","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/jvi.53.3.926-934.1985","article-title":"Rabies virulence: Effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif","year":"1985","journal-title":"J. Virol."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/2\/3\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:45:26Z","timestamp":1760208326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/2\/3\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["tropicalmed2030048"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed2030048","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,20]]}}}